Skip to content

Deal · Funding10 November 2025 · Closed

Iambic Therapeutics raises at least $100 million

Investors include Abingworth, Alexandria Venture Investments and 14 others.

Iambic Therapeutics Issuer · Abingworth Investor · Alexandria Venture Investments Investor · Alumni Ventures Investor · ARK Invest Investor · Ascenta Investor · Catalio Capital Management Investor · Everbright Biofund Investor · Freeflow Ventures Investor · Illumina Ventures Investor · Pegasus Tech Ventures Investor · Qatar Investment Authority Investor · Regeneron Ventures Investor · Sequoia Capital Investor · Tao Capital Partners Investor · Terra Magnum Capital Partners Investor · Wilson Sonsini Goodrich & Rosati Investor

The deal

Type
Funding
Amount
at least $100M
Status
Closed
Round
Round
Post-money
Not recorded
Region
United States
Date
10 November 2025

As of this development: a later development may record new terms.

Lifecycle

  1. AnnouncedNot recorded
  2. Closed10 November 2025 · This development

Investors in this round

Abingworth · Investor

Returning · in the Series B extension of June 2024

Alexandria Venture Investments · Investor

First round with Iambic Therapeutics

Alumni Ventures · Investor

First round with Iambic Therapeutics

ARK Invest · Investor

First round with Iambic Therapeutics

Ascenta · Investor

First round with Iambic Therapeutics

Catalio Capital Management · Investor

Returning · in the Series B of October 2023

Everbright Biofund · Investor

First round with Iambic Therapeutics

Freeflow Ventures · Investor

First round with Iambic Therapeutics

Illumina Ventures · Investor

Returning · in the Series B extension of June 2024

Pegasus Tech Ventures · Investor

First round with Iambic Therapeutics

Qatar Investment Authority · Investor

Returning · in the Series B extension of June 2024

Regeneron Ventures · Investor

First round with Iambic Therapeutics

Sequoia Capital · Investor

Returning · in the Series B of October 2023

Tao Capital Partners · Investor

Returning · in the Series B extension of June 2024

Terra Magnum Capital Partners · Investor

First round with Iambic Therapeutics

Wilson Sonsini Goodrich & Rosati · Investor

First round with Iambic Therapeutics

Six of 16 investors were in an earlier Iambic Therapeutics round.

Iambic Therapeutics’s rounds

3 rounds since 2023 · as disclosed: $250M

Iambic Therapeutics's funding rounds Minutes has recorded
DateRoundAmountPost-moneyLed byReturning
10 November 2025Funding round · this roundat least $100M——6 of 16
18 June 2024Series B extension$50M—Mubadala Capital, Exor Ventures4 of 8
3 October 2023Series B$100M—Ascenta Capital, Abingworth0 of 13

Ownership and exit

Listed

14 October 2026 · IPO · Closed · after 3 rounds since 2023 · The deal

Minutes shows stakes only when a party discloses them.

The parties

Iambic Therapeutics Issuer

4 developments · 4 deals in Minutes

Abingworth Investor

3 developments · 3 deals in Minutes

Alexandria Venture Investments Investor

1 development · 1 deal in Minutes

Alumni Ventures Investor

3 developments · 3 deals in Minutes

More in Healthcare

Past 3 months in Activity →